Proteomic distinction of renal oncocytomas and chromophobe renal cell carcinomas

Vanessa Drendel, Bianca Heckelmann, Christoph Schell, Lucas Kook, Martin L. Biniossek, Martin Werner, Cordula A. Jilg, Oliver SchillingClinical 2018 · DOI

TL;DR

This study uses mass spectrometry-based proteomics to identify distinct protein profiles between renal oncocytomas (ROs) and chromophobe renal cell carcinomas (chRCCs), two kidney tumors with similar appearances. They found that lysosomal proteins are more abundant in chRCCs, while mitochondrial proteins are more common in ROs, and validated these findings for LAMP1 and ITGAV using immunohistochemistry.

What Problem Does This Paper Address?

Distinguishing between benign renal oncocytomas (ROs) and malignant chromophobe renal cell carcinomas (chRCCs) can be challenging for pathologists due to their similar histological features. While genetic and transcriptomic studies have explored these differences, a comprehensive proteomic analysis to identify distinct protein biomarkers has been lacking. This study aims to fill that gap by performing a differential proteome profiling of ROs and early-stage chRCCs to uncover reliable protein markers for their distinction.

Methods

The researchers employed formalin-fixed, paraffin-embedded (FFPE) samples, a common and valuable resource for retrospective studies, to perform their proteomic analysis. They utilized isotopic triplex dimethylation for quantitative comparison across samples, allowing for cohort-wide analysis. This technique labels peptides with stable isotopes, enabling the relative quantification of proteins. They also incorporated a pooled reference standard to serve as a benchmark for all samples, similar to the Super-SILAC approach.

For protein identification and quantification, they used liquid chromatography-tandem mass spectrometry (LC-MS/MS). Data analysis involved MaxQuant for initial processing and then RStudio with the limma package for statistical analysis, specifically to identify differentially expressed proteins while correcting for multiple testing.

To validate their proteomic findings, they performed immunohistochemistry (IHC) on a larger cohort of FFPE samples for two key proteins: lysosomal-associated membrane protein 1 (LAMP1) and integrin alpha-V (ITGAV).

Datasets

The study utilized two cohorts of patient samples:

  • Proteomics Cohort: Six renal oncocytoma (RO) cases and six chromophobe renal cell carcinoma (chRCC) cases were used for the initial proteomic profiling.
  • Immunohistochemistry (IHC) Cohort: A larger, separate cohort consisting of 42 RO cases and 31 chRCC cases was used for validating the expression of LAMP1 and ITGAV.

The proteomic data generated in this study has been deposited in the ProteomeXchange Consortium via the PRIDE partner repository (dataset identifier PXD009300).

Key Insights and Ideas

  • FFPE as a robust source for proteomics: The study demonstrates that FFPE samples, often the only available material for retrospective studies, can be reliably used for quantitative proteomic analysis, validating previous work and expanding its applicability.
  • Proteomic signatures differentiate ROs and chRCCs: The proteomic profiling clearly separated RO and chRCC samples, suggesting distinct underlying molecular mechanisms.
  • Mitochondrial vs. Lysosomal enrichment: A key finding is the enrichment of mitochondrial proteins in ROs and lysosomal proteins in chRCCs. This aligns with existing knowledge about ROs (often associated with mitochondrial abnormalities) and suggests a role for lysosomal pathways in chRCC pathogenesis.
  • LAMP1 and ITGAV as potential biomarkers: The study identified LAMP1 and ITGAV as proteins with differential abundance between the two tumor types, which were then successfully validated by IHC. This highlights their potential as diagnostic markers.
  • Protein vs. mRNA correlation: The authors emphasize that protein levels do not always correlate with mRNA levels, underscoring the importance of direct protein analysis for biomarker discovery.

Key Results

  • The proteomic analysis identified and quantified over 3900 proteins, with more than 2400 proteins consistently quantified in at least four RO and four chRCC cases.
  • A partial least squares discriminant analysis (PLS-DA) clearly separated RO and chRCC proteome profiles.
  • The study identified 51 proteins significantly enriched in RO tissue and 59 proteins significantly enriched in chRCC tissue.
  • Gene ontology (GO) enrichment analysis revealed enrichment of mitochondrial proteins in ROs and lysosomal proteins in chRCCs.
  • Immunohistochemistry confirmed a significantly higher presence of LAMP1 in chRCCs compared to ROs (p < 0.01).
  • Immunohistochemistry also showed a significantly stronger presence of ITGAV in ROs compared to chRCCs (p < 0.01).

Limitations and Future Work

  • Limited sample size for initial proteomic analysis: While the IHC validation used a larger cohort, the initial proteomic profiling was based on only six cases of each tumor type.
  • Focus on early-stage chRCC: The study focused on early-stage chRCCs (T1 or T2), and further investigation into later stages might reveal different proteomic profiles.
  • Correlation with clinical parameters: While the study refers to external data for correlations with survival and tumor stage, direct correlation analysis within their own cohort would strengthen these findings.
  • Future Directions: The authors suggest that their work validates the use of FFPE for retrospective quantitative proteomics and proposes extending this approach to other variants of renal cell neoplasms. They also highlight the potential for novel protein candidates identified in their study to be further investigated as biomarkers.

Summary updated

Abstract

We present one of the first differential proteome profiling studies on ROs and chRCCs and highlight differential abundance of LAMP1 and ITGAV in these renal tumors.
BibTeX
@inproceedings{drendel2018proteomic,
  author = {Vanessa Drendel and Bianca Heckelmann and Christoph Schell and Lucas Kook and Martin L. Biniossek and Martin Werner and Cordula A. Jilg and Oliver Schilling},
  title = {{Proteomic distinction of renal oncocytomas and chromophobe renal cell carcinomas}},
  booktitle = {Clinical},
  year = {2018},
  doi = {10.1186/s12014-018-9200-6},
}
Figure